|Bid||19.02 x 800|
|Ask||19.10 x 4000|
|Day's Range||18.92 - 19.48|
|52 Week Range||18.92 - 42.50|
|Beta (3Y Monthly)||1.59|
|PE Ratio (TTM)||41.26|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.56|
CNBC's "Power Lunch" team discusses generic drug makers' price fixing allegations with Chester "Chip" Davis, CEO of the Association of Accessible Medicines.
Pharmaceutical company Teva is accused of inflating drug prices. The stock plummeting after 44 states accused Teva and 19 other drug companies of driving up the market prices for generic drugs to avoid competition. Yahoo Finance's Seana Smith and Jared Blikre discuss.
Forty-four U.S. states, led by Connecticut Attorney General William Tong, claim that 20 drug companies, including Teva USA, "systematically" divided up the market for generic drugs to avoid competing with one another, according to 500-page lawsuit filed late Friday in the U.S. District Court in Connecticut.
Teva Pharmaceutical and Mylan could be on the hook for billions in damages after a lawsuit accused pharmaceutical companies of colluding to fix generic drug prices, an analyst said Friday.
Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, May 20, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-week safety study at the 2019 American Thoracic Society (ATS) International Conference in Dallas, Texas. YUPELRI® (revefenacin) inhalation solution, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in the U.S.
Aspen Pharmacare said on Monday that Mylan NV had exercised an option to buy the South African drugmaker's portfolio of prescription and over-the-counter products in Australia for 188 million Australian dollars ($130 million). In December, Aspen said its wholly owned subsidiary incorporated in Mauritius, Aspen Global Incorporated, and its Australian subsidiaries had entered into a distribution arrangement with Alphapharm, a subsidiary of Mylan in respect of the portfolio commercialized in Australia and New Zealand. "The divestment is in line with the group's ongoing portfolio management approach and its stated intention to not only acquire value enhancing products, but to also divest of non-core assets, thereby ensuring enhanced operational focus," Aspen said in a statement.
Four posters highlight Mylan's rigorous research and development program HERTFORDSHIRE, England , and PITTSBURGH , May 18, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today ...
HERTFORDSHIRE, England and PITTSBURGH, May 17, 2019 /PRNewswire/ -- Mylan N.V. (MYL) yesterday presented at the Bank of America Merrill Lynch Healthcare Conference, where the company announced that it will host an Investor Day on July 31, 2019 in New York City. CEO Heather Bresch and Mylan's senior leadership team will share the company's long-term strategic plan, including a strong focus on sustaining profitable growth. As an incremental overlay to the strategic plan, leaders also will provide additional detail on the company's plans to refine its product portfolio, new product launch priorities, commercial focus and operations configuration resulting from their in-depth review of market economics and trends and Mylan's competitive position.
The prices of generic drugs across the universe of pharmaceutical companies appeared to stabilize in the first quarter — shucking off years of broad decline, Wall Street analysts say.
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, May 15, 2019 /PRNewswire/ -- Mylan N.V. (MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that final data from the HERITAGE study will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The HERITAGE study compared Ogivri™ to the reference product, Herceptin®, in patients with HER2+ metastatic breast cancer in combination with taxanes for the first 24 weeks and then as a monotherapy until progression.
Teva Pharmaceutical shares continue to fall amid concerns about a lawsuit over alleged price fixing among generic drugmakers.
DEEP DIVE A return to stock-market volatility no doubt has many investors worried. We have seen that over long periods, low-volatility index funds have performed better than their full-index benchmarks.
Shares of Mylan N.V. sank 2.7% in morning trade toward a 7 1/2-year low, after Fitch Ratings revised its outlook on the generic drug maker's credit rating to negative from stable, putting the rating in danger of a downgrade to "junk" status. Mylan's long-term issuer default rating at Fitch is BBB-, the lowest investment-grade rating. Fitch said the revised outlook reflects its expectation that gross leverage may remain elevated over the near term because of slower-than-expected revenue growth, cash generation and debt reduction. Fitch's rating and outlook is similar to S&P Global Ratings' BBB- rating with a negative outlook, while Moody's Investors Service has a Baa3 rating--one notch above "junk"--with a stable outlook. Generic drug maker stocks have been under pressure in recent weeks, and took another header on Monday after more than 40 state attorneys general filed suit against 20 makers of generic medications, alleging a conspiracy to artificially inflate prices and reduce competition. Shares of fellow generic drug maker Teva Pharmaceutical Industries Ltd. slid 6.1% in morning trade to a 1 1/2-year low. Year to date, Mylan's stock has tumbled 27.6% and Teva shares have plunged 26.2%, while the SPDR Health Care Select Sector ETF has gained 1.3% and the S&P 500 has tacked on 13.3%.
AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.
Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Revenue guidance for Europe and Rest of World In the first-quarter earnings conference call, Mylan (MYL) reaffirmed its YoY revenue growth rate guidance in the mid-single
News of China’s retaliatory tariffs sent shares tumbling. The Dow Jones Industrial Average lost 2.38% to close at 25,324.99. The S&P 500 has dropped 2.41% to finish at 2811.87, and the Nasdaq Composite dropped 3.41% to close at 7647.02.
Health-care stocks and drugmakers have suffered from pre-election worries, but JPMorgan says there are still some worth buying.
Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)North America revenue growth trendsDuring its first-quarter earnings conference call, Mylan (MYL) reaffirmed its YoY revenue growth rate guidance of high-single-digits for its